RCKT — Rocket Pharmaceuticals, Inc.
Chart, dilution, float and news for RCKT in the TickerWise workspace.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 299
- Website: https://rocketpharma.com
Latest SEC filings for RCKT
Latest RCKT news
- Rocket Pharma upgraded at Goldman Sachs on Danon disease therapy Read article
- Rocket Pharma updates progress on RP-A501 for Danon disease Read article
- Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility Read article
- Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar Read article
- Rocket Pharmaceuticals (NASDAQ:RCKT) Given “Buy” Rating at Chardan Capital Read article
- Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset Read article
- Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data Transcript Read article
- Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital Read article
Educational tool only — not investment advice.